KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid

ST. LOUIS, Aug. 7 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) (the "Company") today announced that the Company notified certain owners of the Company's Class A and Class B Common Stock, as further described below (the "Reporting Persons"), that the stockholder act...

Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product

EXTON, Pa., Aug. 7 /PRNewswire/ -- Kensey Nash Corporation today announced an agreement whereby the Company will re-acquire the distribution rights, along with the trademark, inventory and other assets associated with the OsseoFit Bone Void Filler product line. Under the terms of the agreemen...

EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research ...

AOBO Announces New Product Launch

NEW YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- - Jingwei Capsules Treat Allergy Symptoms - - Complements Established Boke Nasal Spray Brand - - Diversifies Product Offering with Capsule Formulation - American Oriental Bioengineering, Inc. (N...

Prix Galien USA Announces 2009 Final Candidates

Honorees for Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. 30 gala ceremony NEW YORK, Aug. 7 /PRNewswire-USNewswire/ -- The 2009 Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technolo...

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has agreed to sell an aggregate of four million shares of its common stock at a price to the public of $30.50 per share and $200 million aggregate principal amou...

ThermoGenesis Announces Expanded Collaboration With Celling Technologies

RANCHO CORDOVA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- ThermoGenesis (Nasdaq: KOOL ), a leading supplier of innovative products for processing and storing adult stem cells, today announced an expanded collaboration with Celling Technologies ("Celling"), a subsidiary of SpineSmith, ...

Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. ...

Telik Announces Second Quarter 2009 Financial Results

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today reported a net loss of $5.7 million, or $0.11 per share, for the second quarter ended June 30, 2009, compared with a net loss of $13.6 million, or $0.26 per share, for the comparable period in 2008. ...

deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results

REYKJAVIK, Iceland, August 6 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq: DCGN ) today announced that it will report its second quarter 2009 financial results in a press release to be issued on Monday, August 10, after the close of the market in New York. The company will host a ...

Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast

OMAHA, Neb., Aug. 6 /PRNewswire-FirstCall/ -- Transgenomic Inc. (OTC Bulletin Board: TBIO) announces the following Webcast: What: Transgenomic Inc. Second Quarter 2009 Earnings Release Conference Call When: Wednesday, August 12, 2009 @ 5:...

PharmatrophiX, Initially Funded by the Alzheimer's Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan

Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago "Finding a needle in a haystack - 4 molecules out of a million" NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...

Oncothyreon announces webcast of second quarter 2009 financial results conference call

SEATTLE, Aug. 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its second quarter and year end 2009 financial r...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009. "We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quar...

Interleukin Genetics Announces Conference Call To Discuss Second Quarter 2009 Results

WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI ) announced today that it will host a conference call and webcast on Thursday, August 13, 2009, at 4:30 p.m. EDT to review the Company's business developments and second quarter financial results...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that the United States Food and Drug Administration (FDA) has extended the Pr...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, includin...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

CRANBURY, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced financial results for the second quarter 2009. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced...

ADVENTRX Pharmaceuticals Announces Financing

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gro...

The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical th...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

REDWOOD CITY, Calif., Aug 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial results and business progress for the quarter ended June 30, 2009. Total revenue increased to $36.6 million in the second quarter of 2009 compared w...

SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS

SAN DIEGO, CA, August 4, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and ingredient supply industries,...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...

Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

VANCOUVER, Aug. 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) today announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for laparoscopic, or minimally invasive, gynecology procedures, including hysterectomi...

ETC Biomedical Announces Chamber Sale in India

SOUTHAMPTON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Environmental Tectonics Corporation's (OTC Bulletin Board: ETCC) ("ETC" or the "Company") BioMedical Systems Division has been contracted with Hospimedica International Pvt. Ltd. for the delivery and installation of one BARA-MED((R)) monoplac...

Human Genome Sciences Announces Closing of Public Offering

ROCKVILLE, Md., Aug. 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced the closing of its public offering of 26,697,250 newly issued shares of its common stock at a price to the public of $14.00 per share, which includes 3,482,250 shares sold upon exerc...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that clinical data relating to long-term treatment with Stimuvax were presented at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosi...

Yongye International Announces Branded Store Network Increases Over 40% to 5,000 Stores

BEIJING, Aug. 3 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc. (OTC Bulletin Board: YGII; "Yongye" or the "Company"), a leading developer and distributor of Shengmingsu branded plant and animal nutrient products located in the People's Republic of China, today announced that the num...

Hoya Announces First Quarter Financial Results for FY2010

TOKYO, Japan, August 3 /PRNewswire-FirstCall/ -- HOYA Corporation today announced financial results for the first quarter ended June 30, 2009. Net sales were 94.9 billion yen for the quarter, a 27.0% decrease from 130.1 billion yen in the same period last year, and operating income was 9.2 bil...

Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call

ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) today announced that it will report its 2009 second quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, August 7, 2009. The Company will hold an investor conference ...

Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call

SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced that it plans to issue earnings results for its second quarter and six months ended June 30, 2009, after the close of market on Aug. 6, 2009. The company's earnings conference call w...

IIVS Announces Initiation by EPA of a Pilot Program to Evaluate Non-Animal Eye-Irritation Methods

GAITHERSBURG, Md. , July 30 /PRNewswire-USNewswire/ -- The EPA has initiated a new program to evaluate the use of non-animal methods to replace the Draize test for eye irritation labeling for antimicrobial cleaning products. The is the first program of its kind and demonstrates the Ag...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) today announced plans to develop a DNA-based orthobiologics product portfolio based on research and development by Cardium's Tissue Repair Company that will initially focus on non-union bone fractu...

Micromet Announces Pricing of Public Offering of Common Stock

BETHESDA, Md., July 30 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the pricing of its public offering of 14,000,000 shares of...

Cornerstone Therapeutics Announces Closing of Chiesi Transaction

CARY, N.C., July 30 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it has close...

Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets

BEIJING, July 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported it...

Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results

WALTHAM, Mass., July 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN ) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Thursday, August 6th, 2009 at 10:00 a.m. EDT, to report fi...

Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods ended June 30, 2009. "Clinical results from our monotherapy and combination clinical trials with R...

Micromet Announces Public Offering of Common Stock

BETHESDA, Md., July 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it intends to offer shares of its common st...